Many patients with type 2 diabetes are taking dipeptidyl peptidase 4 inhibitors (DPP-4is) or glucagon-like peptide-1 receptor agonists (GLP1-RAs)—both of which work through the incretin pathway in the gut [2, 7, 8]. This evidence concerns the gene GCG and type 2 diabetes mellitus.